C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy).
about
Targeted immune therapy of ovarian cancerIdentification of ovarian cancer-associated proteins in symptomatic women: A novel method for semi-quantitative plasma proteomics.Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.Circulating inflammation markers and risk of epithelial ovarian cancerInflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC CohortAssociation between high-sensitivity C-reactive protein (hsCRP) and change in mammographic density over time in the SWAN mammographic density subcohort.Using Immune Marker Panels to Evaluate the Role of Inflammation in Cancer: Summary of an NCI-sponsored Workshop.A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patientsOvarian cancer risk factors by tumor dominance, a surrogate for cell of originElevated high-sensitivity C-reactive protein as a risk marker of the attenuated relationship between serum cholesterol and cardiovascular events at older age. The ARIC StudyA prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor α receptor 2 levels and risk of ovarian cancer.Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancer.High-sensitivity C-reactive protein and cancer.The immune system in the pathogenesis of ovarian cancer.Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies.C-reactive protein and risk of ovarian cancer: A systematic review and meta-analysis.Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium.Obesity and Ovarian Cancer.TNF-α expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis?Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.Prognostic evaluation of preoperative serum C-reactive protein concentration in patients with epithelial ovarian cancer.Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer.Insulin-like growth factor-I and C-reactive protein during pregnancy and maternal risk of non-epithelial ovarian cancer: a nested case–control study
P2860
Q28082828-A7868C90-F374-4ACD-9BFD-C0AF3CD6A842Q34244781-27696DB4-A47D-41B2-A3B4-4F1D1C5DF6A6Q34624404-AB192BC0-8E62-46C8-8075-8019009982D0Q34949061-AA1AD047-69EB-49EA-8D69-9D7D3C5FFD11Q35680361-86292C6D-E3EB-4B28-9FF1-A36D67E2644FQ35733402-15DA14F6-EF2B-4970-A205-2E12DB197A4CQ36403297-6E494F7E-DF7A-4000-B64A-5E38B06D8236Q36823174-EE1DF5CD-B3AE-453F-AFE6-52DFAAB923D6Q36948873-82150C91-C75D-42F8-9259-1A6E1A8E2914Q37197634-36E824D5-2C2C-474D-965A-488327CF03CFQ37220800-9C978AB7-5653-4D78-A909-BDF2F8C92379Q37297487-1901DDAB-C78F-43ED-8534-4B2889177A42Q37506191-63DD5A10-E9BC-45C6-AEB8-F18961D2B741Q37613407-E6E98EBA-73DD-4A02-9F91-24A522355AB5Q37972865-727D5D30-D7A9-479F-BA09-13943044F274Q38611475-EC57C497-5E3F-49F6-AAF1-5E0A3C865CEFQ38756834-BF73D280-1D27-4581-A80E-096930B350D8Q38788240-76475E39-FBE1-4BD4-9213-DD94FC815E76Q38882583-EFC98E3C-BC99-4212-B9C7-4ACCE174B12EQ40428099-C1F75260-3ECB-48E7-986A-5160FA5EBA81Q40774077-6F91EE39-FB65-4116-9E9B-D84ADBC49E38Q47142109-85C8C9AF-C891-4F1E-9FDA-8C6514B9DE9BQ57610290-3084387F-2338-4A29-8C6C-CB2BC8DAF574
P2860
C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy).
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
C-reactive protein and ovarian ...... cohorts (Sweden, USA, Italy).
@ast
C-reactive protein and ovarian ...... cohorts (Sweden, USA, Italy).
@en
C-reactive protein and ovarian ...... cohorts (Sweden, USA, Italy).
@nl
type
label
C-reactive protein and ovarian ...... cohorts (Sweden, USA, Italy).
@ast
C-reactive protein and ovarian ...... cohorts (Sweden, USA, Italy).
@en
C-reactive protein and ovarian ...... cohorts (Sweden, USA, Italy).
@nl
prefLabel
C-reactive protein and ovarian ...... cohorts (Sweden, USA, Italy).
@ast
C-reactive protein and ovarian ...... cohorts (Sweden, USA, Italy).
@en
C-reactive protein and ovarian ...... cohorts (Sweden, USA, Italy).
@nl
P2093
P2860
P50
P921
P1476
C-reactive protein and ovarian ...... cohorts (Sweden, USA, Italy).
@en
P2093
Alan A Arslan
Franco Berrino
Laure Dossus
Marianne Wulff
Paolo Toniolo
Tess Clendenen
P2860
P2888
P304
P356
10.1007/S10552-009-9330-2
P50
P577
2009-03-20T00:00:00Z